Form 4: Castle Biosciences CEO Derek Maetzold Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Castle Biosciences CEO Derek Maetzold sold shares of the company's common stock on August 29 and 30, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Derek Maetzold, the President and CEO of Castle Biosciences, sold shares of the company's common stock on August 29 and 30, 2024.
- The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2023.
- On August 29, 2024, Maetzold sold 1,334 shares directly at a weighted average price of $30.075.
- Additional sales were made indirectly through various trusts for the benefit of his descendants and children.
- On August 30, 2024, Maetzold sold 322 shares directly at a weighted average price of $30.099.
- Further indirect sales were made through the same trusts as on August 29, 2024.
- Following these transactions, Maetzold continues to hold a significant number of shares directly and indirectly through various trusts.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to stock sales by an insider. It doesn't inherently convey positive or negative sentiment, as it's a routine disclosure.
Industry Context
This is a routine disclosure of insider trading activity. It is common for executives to use 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information.
Stakeholder Impact
- The stock sales could have a minor negative impact on shareholder sentiment, although the existence of a pre-arranged trading plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| 2023-12-05 | Date of adoption of Rule 10b5-1 trading plan. |
| 2024-08-29 | Date of first reported transaction (stock sale). |
| 2024-08-30 | Date of second reported transaction (stock sale). |
| 2024-09-03 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.